Style | Citing Format |
---|---|
MLA | Bayat N, et al.. "The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model." Asian Pacific Journal of Cancer Prevention, vol. 19, no. 9, 2018, pp. 2553-2560. |
APA | Bayat N, Izadpanah R, Ebrahimibarough S, Javidan AN, Ai A, Ardakan MMM, Saberi H, Ai J (2018). The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model. Asian Pacific Journal of Cancer Prevention, 19(9), 2553-2560. |
Chicago | Bayat N, Izadpanah R, Ebrahimibarough S, Javidan AN, Ai A, Ardakan MMM, Saberi H, Ai J. "The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model." Asian Pacific Journal of Cancer Prevention 19, no. 9 (2018): 2553-2560. |
Harvard | Bayat N et al. (2018) 'The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model', Asian Pacific Journal of Cancer Prevention, 19(9), pp. 2553-2560. |
Vancouver | Bayat N, Izadpanah R, Ebrahimibarough S, Javidan AN, Ai A, Ardakan MMM, et al.. The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model. Asian Pacific Journal of Cancer Prevention. 2018;19(9):2553-2560. |
BibTex | @article{ author = {Bayat N and Izadpanah R and Ebrahimibarough S and Javidan AN and Ai A and Ardakan MMM and Saberi H and Ai J}, title = {The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {19}, number = {9}, pages = {2553-2560}, year = {2018} } |
RIS | TY - JOUR AU - Bayat N AU - Izadpanah R AU - Ebrahimibarough S AU - Javidan AN AU - Ai A AU - Ardakan MMM AU - Saberi H AU - Ai J TI - The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model JO - Asian Pacific Journal of Cancer Prevention VL - 19 IS - 9 SP - 2553 EP - 2560 PY - 2018 ER - |